Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis

Cellular and Molecular Life Sciences

Volumn 60, Issue 1, 2003, Pages 185-197

  Penkowa, M ^a   Espejo, C ^b   Martinez Caceres E M ^b,c   Montalban, X ^b   Hidalgo, J ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Transfusion Center and Tissue Bank   (Spain)

^d INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Demyelination; EAE MS; Metallothionein; Neurodegeneration; Neurotrophic factor; Regeneration

Indexed keywords

METALLOTHIONEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DEMYELINATION; MACROPHAGE; MORBIDITY; MOUSE; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; T LYMPHOCYTE;

ANIMALS; AXONS; BRAIN STEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION; GROWTH CONES; GROWTH SUBSTANCES; METALLOTHIONEIN; MICE; MICE, KNOCKOUT; NERVE GROWTH FACTORS; OLIGODENDROGLIA; SPINAL CORD;

ANIMALIA;

EID: 0037278676     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180300013     Document Type: Article

References (68)

1. Bjartmar C. and Trapp B. D. (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14: 271-278
2. Kornek B., Storch M. K., Weissert R., Wallstroem E., Stefferl A., Olsson T. et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157: 267-276
3. Penkowa M. and Hidalgo J. (2000) Metallothionein I+II (MT-I+II) expression and their role on experimental autoimmune encephalomyelitis (EAE). Glia 32: 247-263
4. Penkowa M. and Hidalgo J. (2001) Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-α and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp. Neurol. 170: 1-14
5. Svensson L., Abdul-Majid K. B., Bauer J., Lassmann H., Harris R. A. and Holmdahl R. (2002) A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur. J. Immunol. 32: 1939-1946
6. Espejo C., Carrasco J., Hidalgo J., Penkowa M., Garcia A., Sáez-Torres I. et al. (2001) Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience 105: 1055-1065
7. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H. et al. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8: 500-508
8. Hidalgo J., Aschner M., Zatta P. and Vasak M. (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res. Bull. 55: 133-145
9. Miles A. T., Hawksworth G. M., Beattie J. H. and Rodilla V. (2000) Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit. Rev. Biochem. Mol. Biol. 35: 35-70
10. Penkowa M. (2002) Metallothionein expression and roles in the central nervous system. Biomed. Rev. 13: 1-18
11. Penkowa M., Espejo C., Martínez-Cáceres E. M., Poulsen C. B. and Hidalgo J. (2001) Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119: 248-260
12. Giralt M., Penkowa M., Lago N., Camats J., Hernandez J., Molinero A. et al. (2002) Metallothionein-1+2 protect the CNS after a focal brain injury. Exp. Neurol. 173: 114-128
13. Penkowa M., Carrasco J., Giralt M., Moos T. and Hidalgo J. (1999) CNS wound healing is severely depressed in metallothionein-I and II-deficient mice. J. Neurosci. 19: 2535-2545
14. Penkowa M., Carrasco J., Giralt M., Molinero A., Hernández J., Campbell I. L. et al. (2000) Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J. Cereb. Blood Flow Metab. 20: 1174-1190
15. Trendelenburg G., Prass K., Priller J., Kapinya K., Polley A., Muselmann C. et al. (2002) Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J. Neurosci. 22: 5879-5888
16. Van Lookeren Campagne M., Thibodeaux H., Van Bruggen N., Caims B., Gerlai R., Palmer J. T. et al. (1999) Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 96: 12870-12875
17. Carrasco J., Penkowa M., Hadberg H., Molinero A. and Hidalgo J. (2000) Enhanced seizures and hippocampal neurodegeneration following kainic acid induced seizures in metallothionein-I+II deficient mice. Eur. J. Neurosci. 12: 2311-2322
18. Penkowa M., Giralt M., Camats J. and Hidalgo J. (2002) Metallothionein 1+2 protect the CNS during neuroglial degeneration induced by 6-aminonicotinamide. J. Comp. Neurol. 444: 174-189
19. Masters B. A., Kelly E. J., Quaife C. J., Brinster R. L. and Palmiter R. D. (1994) Targeted disruption of metallothionein I and II genes increased sensitivity to cadmium. Proc. Natl. Acad. Sci. USA 91: 584-588
20. Gasull T., Rebollo D. V., Romero B. and Hidalgo J. (1993) Development of a competitive double antibody radioimmunoassay for rat metallothionein. J. Immunoassay 14: 209-225
21. Dubois-Dalcq M. and Murray K. (2000) Why are growth factors important in oligodendrocyte physiology? Pathol. Biol. (Paris) 48: 80-86
22. Franklin R. J. (2002) Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3: 705-714
23. Goddard D. R., Berry M. and Butt A. M. (1999) In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system. J. Neurosci. Res. 57: 74-85
24. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mork S. and Bo L. (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338: 278-285
25. Aschner M. (1996) The functional significance of brain metallothioneins. FASEB J. 10: 1129-1136
26. Coyle P., Philcox J. C., Carey L. C. and Rofe A. M. (2002) Metallothionein: the multipurpose protein. Cell. Mol. Life Sci. 59: 627-647
27. Lazo J. S., Kuo S. M., Woo E. S. and Pitt B. R. (1998) The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem.-Biol. Interact. 111-112: 255-262
28. Cassarino D. S. and Bennett J. P. Jr (1999) An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Rev. 29: 1-25
29. Halliwell B. (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716
30. Cross A. H., Manning P. T., Keeling R. M., Schmidt R. E. and Misko T. P. (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 88: 45-56
31. Miljkovic D. J., Drulovic J., Trajkovic V., Mesaros S., Dujmovic I. and Maksimovic D. (2002) Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. Eur. J. Neurol. 9: 413-418
32. Ruuls S. R., Bauer J., Sontrop K., Huitinga I., 't Hart B. A. and Dijkstra C. D. (1995) Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 56: 207-217
33. Scott G. S., Kean R. B., Southan G. J., Szabo C. and Hooper D. C. (2001) Effect of mercaptoethylguanidine scavengers of peroxynitrite on the development of experimental allergic encephalomyelitis in PLSJL mice. Neurosci. Lett. 311: 125-128
34. Cross A. H., Misko T. P., Lin R. F., Hickey W. F., Trotter J. L. and Tilton R. G. (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93: 2684-2690
35. Pozza M., Bettelli C., Aloe L., Giardino L. and Calza L. (2000) Further evidence for a role of nitric oxide in experimental allergic encephalomyelitis: aminoguanidine treatment modifies its clinical evolution. Brain Res. 855: 39-46
36. Jin R., Chow V. T., Tan P. H., Dheen S. T., Duan W. and Bay B. H. (2002) Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23: 81-86
37. Cai L., Wang G. J., Xu Z. L., Deng D. X., Chakrabarti S. and Cherian M. G. (1998) Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res. 18: 4667-4672
38. Jayasurya A., Bay B. H., Yap W. M. and Tan N. G. (2000) Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br. J. Cancer 82: 1198-1203
39. Mates M. (2000) Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153: 83-104
40. Sun A. Y. and Chen Y. M. (1998) Oxidative stress and neurodegenerative disorders. J. Biomed. Sci. 5: 401-414
41. Dalton T., Fu K., Palmiter R. D. and Andrews G. K. (1996) Transgenic mice that overexpress metallothionein-I resist dietary zinc deficiency. J. Nutr. 126: 825-833
42. Kelly E. J. and Palmiter R. D. (1996) A murine model of Menkes disease reveals a physiological function of metallothionein. Nat. Genet. 13: 219-222
43. Kelly E. J., Quaife C. J., Froelick G. J. and Palmiter R. D. (1996) Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. J. Nutr. 126: 1782-1790
44. Choi D. W. and Koh J. Y. (1998) Zinc and brain injury. Annu. Rev. Neurosci. 21: 347-375
45. Sheline C. T., Choi E. H., Kim-Han J. S., Dugan L. L. and Choi D. W. (2002) Cofactors of mitochondrial enzymes attenuate copper-induced death in vitro and in vivo. Ann. Neurol. 52: 195-204
46. Zou K., Gong J. S., Yanagisawa K. and Michikawa M. (2002) A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22: 4833-4841
47. Youn J., Hwang S. H., Ryoo Z. Y., Lynes M. A., Paik D. J., Chung H. S. et al. (2002) Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators. Clin. Exp. Immunol. 129: 232-239
48. Floyd R. A. (1999) Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. 26: 1346-1355
49. Floyd R. A. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222: 236-245
50. Merrill J. E. and Benveniste E. N. (1996) Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19: 331-338
51. Jasani B. and Schmid K. W. (1997) Significance of metallothionein overexpression in human tumours. Histopathology 31: 211-214
52. Kondo Y., Rusnak J. M., Hoyt D. G., Settineri C. E., Pitt B. R. and Lazo J. S. (1997) Enhanced apoptosis in metallothionein null cells. Mol. Pharmacol. 52: 195-201
53. Abdel-Mageed A. and Agrawal K. C. (1997)Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 4: 199-207
54. Ard M. D., Schachner M., Rapp J. T. and Faissner A. (1993) Growth and degeneration of axons on astrocyte surfaces: effects on extracellular matrix and on later axonal growth. Glia 9: 248-259
55. Wujek J. R., Haleem-Smith H., Yamada Y., Lipsky R., Lan Y. T. and Freese E. (1990) Evidence that the B2 chain of laminin is responsible for the neurite outgrowth-promoting activity of astrocyte extracellular matrix. Dev. Brain Res. 55: 237-247
56. Ellison J. A., Barone F. C. and Feuerstein G. Z. (1999) Matrix remodeling after stroke: de novo expression of matrix proteins and integrin receptors. Ann. N. Y. Acad. Sci. 890: 204-222
57. Sayer F. T., Oudega M. and Hagg T. (2002) Neurotrophins reduce degeneration of injured ascending sensory and corticospinal motor axons in adult rat spinal cord. Exp. Neurol. 175: 282-296
58. Ruffini F., Furlan R., Poliani P. L., Brambilla E., Marconi P. C., Bergami A. et al. (2001) Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 8: 1207-1213
59. Cautain B., Damoiseaux J., Bernard I., Straaten H. van, Breda Vriesman P. van, Boneu B. et al. (2001) Essential role of TGF-beta in the natural resistance to experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 31: 1132-1140
60. Arredondo L. R., Deng C., Ratts R. B., Lovett-Racke A. E., Holtzman D. M. and Racke M. K. (2001) Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 31: 625-633
61. Alberch J., Perez-Navarro E. and Canals J. M. (2002) Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res. Bull. 57: 817-822
62. Douni E., Akassoglou K., Alexopoulou L., Georgopoulos S., Haralambous S., Hill S. et al. (1995-1996) Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J. Inflamm. 47: 27-38
63. Okuda Y., Sakoda S., Fujimura H., Saeki Y., Kishimoto T. and Yanagihara T. (1999) IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 101: 188-196
64. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G. and Kollias G. (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 92: 11294-11298
65. Samoilova E. B., Horton J. L., Hilliard B., Liu T. S. and Chen Y. (1998) IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161: 6480-6486
66. Chen H., Carlson E. C., Pellet L., Moritz J. T. and Epstein P. N. (2001) Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50: 2040-2046
67. Ohly P., Dohle C., Abel J., Seissler J. and Gleichmann H. (2000) Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia 43: 1020-1030
68. Lansdown A. B. (2002) Metallothioneins: potential therapeutic aids for wound healing in the skin. Wound Repair Regen. 10: 130-132